Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Immunoglobulin A nephropathy (IgAN) is a primary glomerulonephritis with heterogenous clinical manifestations, progression rates, and outcomes. New treatments for IgAN aim to alter the disease course by targeting the underlying pathophysiology. Zigakibart, a humanized, monoclonal anti-A PRoliferation-Inducing Ligand (APRIL) antibody, has shown sustained and clinically meaningful proteinuria reduction, durable reductions in galactose-deficient immunoglobulin A1 (Gd-IgA1) levels, and estimated glomerular filtration rate (eGFR) stabilization in adults with IgAN. The SHIFT study aims to substantiate evidence of clinical efficacy by including on-treatment biopsies to directly show the impact of zigakibart treatment on the kidney histology.
Adults with biopsy-confirmed IgAN (biopsy ≤5 years prior), eGFR ≥45 mL/min/1.73 m and persistent proteinuria (≥0.5 g/d) despite supportive therapy (angiotensin-converting enzyme inhibitors, angiotensin receptor blocker, sodium–glucose co-transporter 2 inhibitors, etc.) will be enrolled in this open-label, multicenter study. Recently diagnosed patients (within ≤6 months) do not need to wait for optimization of supportive therapy if their proteinuria was initially ≥1.5 g/d and may use their diagnostic biopsy as pretreatment baseline (BL). Key exclusion criteria: serum IgG levels <6.0 g/L, planned or recently initiated treatment with glucagon-like peptide-1 receptor agonists, other anti-APRIL or anti-APRIL/B-cell activating factor use. The baseline biopsy will not be used as an eligibility determinant. Participants will be randomized 1:1 to undergo an on-treatment biopsy either at the end of Year 1 or Year 2 (Figure). Primary endpoint: change from BL (CFB) in glomerular IgA deposition by immunofluorescence at weeks 52 and 104. Key secondary endpoints: CFB in mesangial hypercellularity, endocapillary hypercellularity, segmental glomerulosclerosis, tubular atrophy or interstitial fibrosis, and (fibro)cellular crescents (MEST-C) score, cluster of differentiation 68+, C3c staining, proteinuria, hematuria, eGFR, Gd-IgA, IgA, IgG, IgM levels, safety, tolerability, and pharmacokinetics.
The SHIFT study aims to demonstrate the disease-modifying effect of zigakibart while characterizing the time course of changes in clinical and laboratory markers of kidney disease during a 2-year treatment period. This abstract was also submitted for presentation at the American Society of Nephrology 2025 congress and re-submitting the abstract has been permitted by the congress.
